Titre : Chrysosporium

Chrysosporium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Depression
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chrysosporium : Questions médicales les plus fréquentes", "headline": "Chrysosporium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chrysosporium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chrysosporium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Deuteromycota", "url": "https://questionsmedicales.fr/mesh/D003904", "about": { "@type": "MedicalCondition", "name": "Deuteromycota", "code": { "@type": "MedicalCode", "code": "D003904", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B01.300.381" } } }, "about": { "@type": "MedicalCondition", "name": "Chrysosporium", "alternateName": "Chrysosporium", "code": { "@type": "MedicalCode", "code": "D002912", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anwei Chen", "url": "https://questionsmedicales.fr/author/Anwei%20Chen", "affiliation": { "@type": "Organization", "name": "College of Resources and Environment, Hunan Agricultural University, Changsha 410128, PR China. Electronic address: A.Chen@hunau.edu.cn." } }, { "@type": "Person", "name": "Liang Hu", "url": "https://questionsmedicales.fr/author/Liang%20Hu", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China. Electronic address: huliang2018@csu.edu.cn." } }, { "@type": "Person", "name": "Sheng-Tao Yang", "url": "https://questionsmedicales.fr/author/Sheng-Tao%20Yang", "affiliation": { "@type": "Organization", "name": "College of Chemistry and Environment Protection Engineering, Southwest Minzu University, Chengdu, 610041, PR China. Electronic address: yangst@pku.edu.cn." } }, { "@type": "Person", "name": "Ni He", "url": "https://questionsmedicales.fr/author/Ni%20He", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China." } }, { "@type": "Person", "name": "Motoyuki Shimizu", "url": "https://questionsmedicales.fr/author/Motoyuki%20Shimizu", "affiliation": { "@type": "Organization", "name": "Department of Applied Biological Chemistry, Faculty of Agriculture, Meijo University, Nagoya, Aichi 468-8502, Japan. Electronic address: moshimi@meijo-u.ac.jp." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Neurophysiological markers of depression detection and severity prediction in first-episode major depressive disorder.", "datePublished": "2023-03-20", "url": "https://questionsmedicales.fr/article/36940824", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jad.2023.03.038" } }, { "@type": "ScholarlyArticle", "name": "Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36702062", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.comppsych.2023.152365" } }, { "@type": "ScholarlyArticle", "name": "Transitions in depression: if, how, and when depressive symptoms return during and after discontinuing antidepressants.", "datePublished": "2022-11-23", "url": "https://questionsmedicales.fr/article/36418524", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11136-022-03301-0" } }, { "@type": "ScholarlyArticle", "name": "Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.", "datePublished": "2022-09-01", "url": "https://questionsmedicales.fr/article/36103181", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2022.30367" } }, { "@type": "ScholarlyArticle", "name": "Treatment-resistant depression and major depression with suicide risk-The cost of illness and burden of disease.", "datePublished": "2022-08-11", "url": "https://questionsmedicales.fr/article/36033799", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.898491" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Eucaryotes", "item": "https://questionsmedicales.fr/mesh/D056890" }, { "@type": "ListItem", "position": 3, "name": "Champignons", "item": "https://questionsmedicales.fr/mesh/D005658" }, { "@type": "ListItem", "position": 4, "name": "Deuteromycota", "item": "https://questionsmedicales.fr/mesh/D003904" }, { "@type": "ListItem", "position": 5, "name": "Chrysosporium", "item": "https://questionsmedicales.fr/mesh/D002912" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chrysosporium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chrysosporium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chrysosporium", "description": "Comment diagnostiquer une infection par Chrysosporium ?\nQuels tests sont utilisés pour identifier Chrysosporium ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes indiquent une infection par Chrysosporium ?\nPeut-on utiliser des tests sérologiques pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chrysosporium", "description": "Quels sont les symptômes courants d'une infection fongique ?\nLes infections cutanées par Chrysosporium sont-elles fréquentes ?\nComment se manifestent les infections pulmonaires ?\nLes infections systémiques sont-elles graves ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chrysosporium", "description": "Comment prévenir les infections par Chrysosporium ?\nLes personnes immunodéprimées doivent-elles prendre des précautions ?\nLe port de gants est-il recommandé lors de manipulations ?\nLes vaccinations aident-elles à prévenir ces infections ?\nL'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chrysosporium", "description": "Quels traitements sont efficaces contre Chrysosporium ?\nLes traitements varient-ils selon la gravité de l'infection ?\nCombien de temps dure le traitement antifongique ?\nDes effets secondaires sont-ils associés aux antifongiques ?\nLes infections par Chrysosporium nécessitent-elles une hospitalisation ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chrysosporium", "description": "Quelles complications peuvent survenir avec Chrysosporium ?\nLes infections par Chrysosporium peuvent-elles être mortelles ?\nComment les complications sont-elles gérées ?\nLes complications affectent-elles le pronostic ?\nLes infections récurrentes sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chrysosporium", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection fongique ?\nLes traitements immunosuppresseurs sont-ils un facteur de risque ?\nLes voyages dans des zones tropicales augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Depression&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Chrysosporium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen microscopique et la culture du champignon." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Chrysosporium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture et des techniques moléculaires comme la PCR peuvent être utilisés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être nécessaires pour confirmer l'infection fongique." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par Chrysosporium ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des lésions cutanées, des infections pulmonaires ou systémiques." } }, { "@type": "Question", "name": "Peut-on utiliser des tests sérologiques pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques ne sont généralement pas fiables pour Chrysosporium." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une infection fongique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, toux, éruptions cutanées et fatigue." } }, { "@type": "Question", "name": "Les infections cutanées par Chrysosporium sont-elles fréquentes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des lésions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment se manifestent les infections pulmonaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles se manifestent par une toux persistante, des douleurs thoraciques et des difficultés respiratoires." } }, { "@type": "Question", "name": "Les infections systémiques sont-elles graves ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être graves et nécessitent une attention médicale immédiate." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état immunitaire." } }, { "@type": "Question", "name": "Comment prévenir les infections par Chrysosporium ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'exposition à des environnements humides et à des matériaux contaminés aide à prévenir." } }, { "@type": "Question", "name": "Les personnes immunodéprimées doivent-elles prendre des précautions ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent éviter les environnements à risque et consulter un médecin régulièrement." } }, { "@type": "Question", "name": "Le port de gants est-il recommandé lors de manipulations ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le port de gants lors de la manipulation de terre ou de matériaux potentiellement contaminés est conseillé." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir ces infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'existe pas de vaccin spécifique contre les infections par Chrysosporium." } }, { "@type": "Question", "name": "L'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hygiène personnelle peut réduire le risque d'infections fongiques." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre Chrysosporium ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antifongiques comme l'itraconazole et le voriconazole sont souvent utilisés." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la gravité de l'infection ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections légères peuvent être traitées par voie orale, tandis que les cas graves nécessitent une perfusion." } }, { "@type": "Question", "name": "Combien de temps dure le traitement antifongique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement peut varier de plusieurs semaines à plusieurs mois selon la gravité." } }, { "@type": "Question", "name": "Des effets secondaires sont-ils associés aux antifongiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées et des problèmes hépatiques peuvent survenir." } }, { "@type": "Question", "name": "Les infections par Chrysosporium nécessitent-elles une hospitalisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité de l'infection; les cas graves peuvent nécessiter une hospitalisation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Chrysosporium ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections systémiques graves et des lésions pulmonaires." } }, { "@type": "Question", "name": "Les infections par Chrysosporium peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en particulier chez les personnes immunodéprimées, elles peuvent être fatales." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent des traitements antifongiques intensifs et un suivi médical." } }, { "@type": "Question", "name": "Les complications affectent-elles le pronostic ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de complications peut aggraver le pronostic et prolonger la durée de traitement." } }, { "@type": "Question", "name": "Les infections récurrentes sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections récurrentes peuvent survenir, surtout chez les patients immunodéprimés." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'immunodépression, le diabète et l'exposition à des environnements humides." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru en raison d'un système immunitaire affaibli." } }, { "@type": "Question", "name": "Le diabète augmente-t-il le risque d'infection fongique ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les traitements immunosuppresseurs sont-ils un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques." } }, { "@type": "Question", "name": "Les voyages dans des zones tropicales augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages dans des zones tropicales peuvent exposer à des agents pathogènes fongiques." } } ] } ] }

Sources (10000 au total)

Neurophysiological markers of depression detection and severity prediction in first-episode major depressive disorder.

Deviant γ auditory steady-state responses (γ-ASSRs) have been documented in some psychiatric disorders. Nevertheless, the role of γ-ASSR in drug-naïve first-episode major depressive disorder (FEMD) pa... Cortical reactivity was assessed in a cohort of 28 FEMD patients relative to 30 healthy control (HC) subjects during an ASSR paradigm randomly presented at 40 and 60 Hz. Event-related spectral perturb... FEMD patients exhibited significantly inferior 40 Hz-ASSR-ITC in the right hemisphere versus HC subjects (p = 0.007), along with attenuated θ-ITC that reflected underlying impairments in θ responses d... Our findings provide critical insight into the pathological mechanism of FEMD, suggesting first that 40 Hz-ASSR-ITC and θ-ITC in right hemisphere constitute potential neurophysiological markers for ea...

Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity.

The past few decades have seen the emergence both of new neuromodulation treatment protocols and novel applications of standard neuromodulation interventions in psychiatry. Yet little is known about d... We administered an online survey with an embedded video vignette experiment to four national samples: the general public (N = 1022), caregivers for people with depression (N = 1026), patients living w... Our results provide evidence that psychiatrists views differ significantly in important ways from other stakeholder groups. Type of intervention also shaped participants' attitudes, including percepti... Given the differing affective valence among stakeholders and the differences found by modality and stakeholder groups across the different scales, future targeted educational initiatives could be deve...

Transitions in depression: if, how, and when depressive symptoms return during and after discontinuing antidepressants.

The aim of the current study is to provide insight into if, how, and when meaningful changes occur in individual patients who discontinue antidepressant medication. Agreement between macro-level quant... During and shortly after antidepressant discontinuation, depressive symptoms and 'feeling down' were measured in 56 participants, using the SCL-90 depression subscale weekly (macro-level) for 6 months... At the macro-level, an increase in depressive symptoms was found in 58.9% of participants that (a) was statistically reliable, (b) persisted for 3 weeks and/or required intervention, and (c) was clini... Meaningful change is common in patients discontinuing antidepressants, and there is substantial heterogeneity in how and when these changes occur. Depressive symptom change at the macro-level is not t...

Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Insufficient treatment response and resulting chronicity constitute a major problem in depressive disorders. Remission rates range as low as 15% to 40% and treatment-resistant depression (TRD) is asso... To determine whether 6 weeks of minocycline as add-on to antidepressant treatment as usual can significantly reduce depressive symptoms in patients with TRD.... The study was conducted in Germany and designed as a multicenter double-blind randomized clinical trial (RCT) of 200 mg/d minocycline treatment over a course of 6 weeks with a 6-month follow-up. Parti... Participants were randomized (1:1) to receive adjunct minocycline (200 mg/d) or placebo for 6 weeks.... Primary outcome measure was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 6 analyzed by intention-to-treat mixed model repeated measures. Secondary outcom... Of 173 eligible and randomized participants (84 randomized to minocycline and 89 randomized to placebo), 168 formed the intention-to-treat sample (79 [47.0%] were women, 89 [53.0%] were men, 159 [94.6... In this large randomized clinical trial with minocycline at a dose of 200 mg/d added to antidepressant treatment as usual for 6 weeks, minocycline was well tolerated but not superior to placebo in red... EU Clinical Trials Register Number: EudraCT 2015-001456-29....

Treatment-resistant depression and major depression with suicide risk-The cost of illness and burden of disease.

Treatment-Resistant Depression (TRD) and Major Depression with Suicide Risk (MDSR) are types of depression with relevant effects on the health of the population and a potentially significant economic ... The disease burden for adults was quantified in 2017 using the Disability-Adjusted Life Years (DALYs) lost. Direct costs related to the health care system and indirect costs were estimated for 2017, w... The estimated prevalence of TRD, MDSR, and both types of depression combined was 79.4 thousand, 52.5 thousand, and 11.3 thousand patients, respectively. The disease burden (DALY) due to the disability... Although TRD and MDSR represent relatively small direct costs for the health system, they have a relevant disease burden and extremely substantial productivity costs for the Portuguese economy and soc...

Emotion Context Insensitivity is generalized in individuals with major depressive disorder but not in those with subclinical depression.

Depressed individuals experience deficits in emotional reactivity. One well-established theory is the Emotion Context Insensitivity (ECI) theory. To better understand impairments in emotional reactivi... Participants were divided into four groups: Major Depressive Disorder Group (MDD, N = 60), Control Group for MDD (Control... The MDD group was more insensitive to both monetary reward and loss across most types of affect than was the control group. Compared with the controls, the SD group exhibited lower reactivity in antic... Emotional affect was evaluated by subjective ratings, which may lack objectivity. Additionally, laboratory settings and monetary rewards used in this study may cause the results less generalized to da... The pattern of emotional reactivity in the MDD group was partly consistent with the ECI theory, whereas the SD group showed greater arousal and instability of emotional reactions. These different patt...

Body mass index and inflammation in depression and treatment-resistant depression: a Mendelian randomisation study.

Major depressive disorder (MDD) has a significant impact on global burden of disease. Complications in clinical management can occur when response to pharmacological modalities is considered inadequat... We used the European UK Biobank subcohort ([Formula: see text]), the mental health questionnaire (MHQ) and clinical records. For treatment resistance, a previously curated phenotype based on general p... In univariable MR models, genetically predicted BMI was positively associated with depression outcomes, including MDD ([Formula: see text] ([Formula: see text] CI): 0.133(0.072, 0.205)) and TRD (0.347... Our work supports the assertion that BMI exerts a causal effect on a range of clinical and questionnaire-based depression phenotypes, with the effect being stronger in females and in younger individua...

Familial risk for major depression: differential white matter alterations in healthy and depressed participants.

Major depressive disorder (MDD) has been associated with alterations in brain white matter (WM) microstructure. However, diffusion tensor imaging studies in biological relatives have presented contrad... In a 2 (MDD v. healthy controls, HC) × 2 (familial risk yes v. no) design, we investigated fractional anisotropy (FA) via tract-based spatial statistics in a large well-characterised adult sample (... Analyses revealed a significant main effect of diagnosis on FA in the forceps minor and the left superior longitudinal fasciculus (... We found widespread increased FA in HC with familial risk for MDD as compared to a HC low-risk sample. The significant effect of risk on FA was present only in HC, but not in the MDD sample. These alt...